Study of Fluoxetine in Autism

PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Autistic Disorder
Interventions
DRUG

Fluoxetine

Once daily oral dispersible tablet 2mg 9mg or 18mg

DRUG

Placebo

Oral dispersible tablet placebo

Trial Locations (17)

10029

Mount Sinai School of Medicine, New York

11714

Long Island Jewish Hospital, Bethpage

15203

Western Psychiatric Institute and Clinic/ Merck Child Outpatient Clinic, Pittsburgh

27514

University of North Carolina, Chapel Hill

30080

Institute for Behavioral Medicine, Smyrna

32611

University of Florida, Department of Psychiatry, Gainesville

43210

Ohio State University, Columbus

48201

Children's Hospital of Michigan, Detroit

60563

AMR-Baber Research Inc., Naperville

77090

Red Oak Psychiatry Associates, Houston

85006

Southwest Autism Research and Resource Centre, Phoenix

89128

Center for Psychiatry and Behavioral Medicine, Las Vegas

95817

University of California Davis, Sacramento

60637-1448

University of Illinois, Chicago

02155

Harvard Medical School, Medford

08043

CRCNJ, Voorhees Township

98105-0371

Seattle Children's Hosptial University of Washington, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Autism Speaks

OTHER

lead

Neuropharm

INDUSTRY